The Mounjaro injectable pen: what the evidence actually shows

What the SURMOUNT programme established about the pen

SURMOUNT-1 randomised 2,539 adults with obesity and without type 2 diabetes. At 72 weeks, participants using the 15mg dose lost an average of around 20–21% of body weight. That figure comes from a controlled trial environment with lifestyle support alongside the medicine, so individual results outside that setting vary, worth saying plainly. The trial also showed meaningful losses at 5mg and 10mg, so people who don't reach the highest dose aren't left without effect.

The SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, compared tirzepatide directly against semaglutide 2.4mg in 751 adults with obesity. Tirzepatide produced greater average weight reduction over 72 weeks. Neither trial tells you exactly what will happen to you specifically, that depends on your starting weight, your health picture, and how your body responds. It does establish that the pen's mechanism, acting on both GIP and GLP-1 receptors rather than GLP-1 alone, appears to translate into stronger average results than a single-pathway injection, and if you're curious about whether tirzepatide comes as an oral medicine or an injectable, that page sets out exactly how the two forms compare.

If you want to read more about how tirzepatide works as an injectable medicine, that page goes into the receptor science in more depth. For the NICE recommendation built from this evidence base, NICE technology appraisal TA1026 is the official UK source.

Using the KwikPen: the practical side

Each Mounjaro KwikPen is a pre-filled disposable device containing four doses at one fixed strength. You use one dose per week; you do not draw up or measure anything. The pen injects into the subcutaneous tissue of the abdomen, outer thigh or upper arm, rotating the site each week reduces the chance of localised skin reactions.

A misconception that comes up regularly: some people assume the pen needs priming or air-bubble expelling like an older-style insulin pen. It doesn't. The KwikPen is designed for single-patient use with no priming step. The Mounjaro SmPC on the eMC contains the full injection technique, step by step, and should be your reference for anything specific to your device, not a forum thread.

Store the pen in the fridge at 2–8°C. There is a limited room-temperature window for travel or if refrigeration isn't available; the SmPC and the Patient Information Leaflet that comes with your pen state the exact duration, refer to those rather than any figure you find online, because the number matters. Used pens and needles go into a sharps container; if you need one, a sharps container is available from the nume pharmacy.

Needle change before each injection is standard practice. The pen does not come supplied with needles attached for each use; your compatible needles are used once and then disposed of safely.

Side effects and when to get medical help

The most common effects are gastrointestinal: nausea, diarrhoea, constipation, indigestion, burping, and sometimes vomiting. These tend to be most noticeable after the first few doses or following a dose increase, and for most people they settle within a couple of weeks. Fatigue, headache and injection-site reactions also appear in the data.

Acute pancreatitis is a less common but more serious concern. In January 2026, the MHRA issued a formal Drug Safety Update flagging it as a known infrequent effect across GLP-1 medicines. If you develop severe, persistent stomach pain that radiates through to your back (with or without vomiting) stop the pen and seek urgent medical attention. Report any suspected side effect through the MHRA's Yellow Card scheme; that reporting helps build the safety picture for everyone.

Tirzepatide is not recommended during pregnancy, while breastfeeding, or if you are actively trying to conceive. It is not licensed for under-18s. People with a personal or family history of medullary thyroid carcinoma or MEN2 should discuss this with a prescriber before starting. The Mounjaro injection page covers the full side-effect profile and contraindications in more detail.

Who the pen is licensed for, and how costs compare to what's included

The UK licence covers adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, type 2 diabetes, obstructive sleep apnoea, high cholesterol or cardiovascular disease. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber weighs those criteria against your full health picture; the licence is a starting point, not a guarantee of suitability.

On the cost side, it helps to read what Mounjaro prices in the UK actually include. Eli Lilly raised the list price substantially from September 2025, and private prices since then typically range from roughly £149 to £375 per month depending on dose and provider. That variance partly reflects what providers bundle in, or don't. At nume, one price covers the consultation, the prescription, the medicine and free next-working-day tracked delivery; there is no separate prescription fee or aftercare charge.

If you're weighing an injectable against an oral route, this comparison of tirzepatide tablets versus injections lays out the practical differences. And if you'd like to understand how body composition tends to shift on Mounjaro over the first weeks, that page draws on what the trial data shows about the sequence.

A prescriber at nume reviews every consultation personally, a real clinician reads your answers, not software. If you'd like that conversation, speak to our prescribers and we'll assess whether Mounjaro is the right fit for you.